Currently, anti-PD1 (nivolumab, pembrolizumab), anti-PDL1 (atezolizumab, avelumab, durvalumab) and anti-CTLA-4 (ipilimumab, tremelimumab) monoclonal antibodies (mAbs) represent the ICI landscape for RCC [3]. The gene discussed is PDCD1; the disease is renal cell carcinoma.